(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 August 2008 (14.08.2008)

PCT

(10) International Publication Number
WO 2008/097664 A1

(51) International Patent Classification:
A61K 9/12 (2006.01) *A61K 9/72* (2006.01)
A61K 31/48 (2006.01) *A61P 25/06* (2006.01)

(21) International Application Number:
PCT/US2008/001829

(22) International Filing Date:
11 February 2008 (11.02.2008)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/900,850 11 February 2007 (11.02.2007) US

(71) Applicant *(for all designated States except US)*: **MAP PHARMACEUTICALS, INC.** [US/US]; 2400 Bayshore Parkway, Suite 200, Mountain View, CA 94043 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **COOK, Robert, O.** [GB/US]; 232 Rosilie Street, San Mateo, CA 94403 (US). **SHREWSBURY, Stephen, B.** [GB/US]; 227 Van Kassel Court, San Anselmo, CA 94960 (US). **RAMADAN, Nabih, N.** [US/US]; 20 Suffolk Lane, Lake Forest, IL 60045 (US). **ARMER, Thomas, A.** [US/US]; 19000 Tilson Avenue, Cupertino, CA 95104 (US).

(74) Agents: **BASU, Shantanu** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: METHOD OF THERAPEUTIC ADMINISTRATION OF DHE TO ENABLE RAPID RELIEF OF MIGRAINE WHILE MINIMIZING SIDE EFFECT PROFILE




Figure 2

(57) Abstract: Pharmaceutical compositions containing dihydroergotamine (DHE) and methods in which DHE is administered to patients for treatment of migraine without side effects or adverse effects are disclosed. Methods for rapid treatment of migraine with DHE are disclosed comprising: dampening the peak plasma concentration (Cmax) and slightly delaying the peak such as to avoid activating the dopaminergic and adrenergic receptors, while achieving sufficient active binding to the serotonin receptors to provide relief from migraine symptoms within a timeframe that permits rapid resolution of migraine symptoms. Inhaler devices suitable for the methods are disclosed. Kits for practicing the methods of invention are disclosed.

WO 2008/097664 A1

Published:

— *with international search report*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*